Context Therapeutics rises after acquiring experimental cancer therapy for $3.75 mln
10/07/2024 16:33
** Shares of Context Therapeutics CNTX.O rise 2.8% to
$2.00
** Drug developer says it has acquired an experimental
cancer therapy from privately-held Link Immunotherapeutics
** CNTX made a one-time payment of $3.75 mln
** Co to start an early-stage trial on the therapy CT-95 in
Q1 2025
** YTD, stock up 77.3%
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Context Therapeutics
See all newsContext Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202